Stallergenes Greer Expands into the Nordic Region with the Establishment of an Affiliate Dedicated to the Danish, Norwegian and Swedish Markets
Stallergenes Greer, a global leader in allergen immunotherapy (AIT), is pleased to announce its expansion into the Nordic region with the establishment of an affiliate dedicated to the Danish, Norwegian, and Swedish markets. Stallergenes Greer Danmark ApS provides the medical community and patients with a fully registered portfolio of sublingual tablet treatments for grass pollen and house dust mite-induced allergic rhinitis.
In Europe, allergic rhinitis affects 1 in 5 people (19% prevalence)1, a proportion that has been increasing over the past decades. It is mostly caused by aeroallergens such as pollen or house dust mites, triggering nasal and ocular symptoms that can impair daily life and potentially progress to allergic asthma—a chronic and debilitating condition affecting 15% to 38% of patients with allergic rhinitis2.
“We are delighted to enter the Nordic region and contribute to improving the quality of life for patients with grass pollen and house dust mite allergies. With the establishment of Stallergenes Greer Danmark ApS, allergy sufferers and physicians in Denmark, Norway, and Sweden can rely on Stallergenes Greer’s dedication to providing effective, high-quality, and clinically proven allergen immunotherapy treatments”, says Brice Chouquet, Country Manager for the Nordic region. Finland will follow in 2025.
The expansion of Stallergenes Greer’s geographic footprint into the Nordic region is a testament to the Group’s commitment to providing patients and healthcare professionals worldwide with comprehensive allergy care. With nearly 120 years of expertise in allergy and allergen immunotherapy (AIT), Stallergenes Greer has an extensive global presence and significant capacity for allergen and finished AIT product manufacturing. Building on its longstanding expertise in allergen immunotherapy, Stallergenes Greer’s innovative treatments are designed to address the specific needs of allergy sufferers.
ABOUT STALLERGENES GREER DANMARK APS
Stallergenes Greer Danmark ApS is a subsidiary of Stallergenes Greer AG, a global healthcare company based in Baar, Switzerland, specializing in the diagnosis and treatment of respiratory, food, and venom allergies through the development and commercialization of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (registered in the United States) and Stallergenes SAS (registered in France). For more information, visit www.stallergenesgreer.com.
- Savouré et al., Worldwide prevalence of rhinitis in adults: A review of definitions and temporal evolution, Clin and Translat Allergy 2022 Vol. 12 Issue 3, article e12130.
- Brozek et al., Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016, revision J Allergy Clin Immunol 2017 Vol. 140 Issue 4 Pages 950-958.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241024900607/en/
Contacts
Stallergenes Greer Danmark ApS
Business Center - Rådhuspladsen 16 - 1550 København - Danmark
CVR 44474492
Email: hello.nordics@stallergenesgreer.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press Release
Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press Release
The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press Release
Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor
Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press Release
Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom